This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences, Cas. Active years: 2008-2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2008-2010
Title: Xiangyin Kong: Innovator in Genetic Research
Introduction
Xiangyin Kong is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of genetic research, particularly in the diagnosis and treatment of various medical conditions. With a total of 3 patents to his name, his work has the potential to impact many lives.
Latest Patents
Kong's latest patents include a method for diagnosing and treating lesions of the crystalline lens using the human CRYGS gene and its coding product. This innovative method focuses on detecting variations in the CRYGS gene, transcript, and/or protein in individuals, which may indicate a higher likelihood of cataract development. Additionally, he has developed a patent related to a baldness-related gene and the polypeptide it encodes. This invention outlines a process for producing the polypeptide through recombinant methods and discusses the use of the Rhor gene and protein in diagnosing and treating baldness.
Career Highlights
Throughout his career, Xiangyin Kong has worked with esteemed institutions such as the Chinese Academy of Sciences and the Shanghai Institutes for Biological Sciences. His research has been pivotal in advancing our understanding of genetic factors in various health conditions.
Collaborations
Kong has collaborated with notable colleagues, including Guoping Zhao and Landian Hu, to further his research endeavors. Their combined expertise has contributed to the success of his innovative projects.
Conclusion
Xiangyin Kong's work in genetic research exemplifies the impact of innovation in medicine. His patents not only showcase his inventive spirit but also hold promise for future advancements in the diagnosis and treatment of critical health issues.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile